DEFA1B: A Protein Involved in Appetite and Body Weight Regulation

Target Name: DEFA1B

NCBI ID: G728358

DEFA1B

DEFA1B: A Protein Involved in Appetite and Body Weight Regulation

DEFA1B (doublecortin) is a protein that is expressed in the hypothalamus, which is the part of the brain that regulates hunger and thirst. It has been shown to play a role in the regulation of body weight and appetite, and is potential drug target for the treatment of obesity and related disorders.

The hypothalamus is a small structure located at the base of the brain that is responsible for regulating a wide range of physiological processes. It is one of the most highly conserved regions of the brain, and has been studied extensively in the past to understand its role in the regulation of appetite and body weight.

DEFA1B is a protein that is expressed in the hypothalamus and is involved in the regulation of appetite and body weight. It is a 21-kDa protein that is composed of two distinct subunits, A and B. The subunit A is a 12kDa protein that is involved in the regulation of appetite, while the subunit B is a 90kDa protein that is involved in the regulation of body weight.

Studies have shown that DEFA1B is involved in the regulation of appetite by controlling the release of a hormone called ghrelin. Ghrelin is a hormone that is produced by the obese and helps to regulate their appetite. Studies have shown that obese individuals have lower levels of DEFA1B compared to lean individuals, and that increasing levels of DEFA1B can lead to an increase in ghrelin release and a decrease in appetite.

In addition to its role in the regulation of appetite, DEFA1B is also involved in the regulation of body weight. Studies have shown that DEFA1B is involved in the regulation of body weight by controlling the sensitivity of muscle cells to the hormone leptin. Leptin is a hormone that is produced by the body and helps to regulate body weight. Studies have shown that obese individuals have lower levels of DEFA1B compared to lean individuals, and that increasing levels of DEFA1B can lead to an increase in muscle resistance to leptin, which can lead to an increase in body weight.

The potential drug target for DEFA1B is the treatment of obesity and related disorders. obesity is a serious public health issue that is associated with a wide range of negative consequences, including increased risk of cardiovascular disease, diabetes, and certain cancers. The development of effective drugs that target DEFA1B and other hypothalamic hormones is a promising approach to the treatment of obesity and related disorders.

In conclusion, DEFA1B is a protein that is expressed in the hypothalamus and is involved in the regulation of appetite and body weight. It is a potential drug target for the treatment of obesity and related disorders. Further research is needed to fully understand the role of DEFA1B in the regulation of appetite and body weight, and to develop effective treatments for obesity.

Protein Name: Defensin Alpha 1B

Functions: Effector molecule of the innate immune system that acts via antibiotic-like properties against a broad array of infectious agents including bacteria, fungi, and viruses or by promoting the activation and maturation of some APCs (PubMed:15616305, PubMed:17142766, PubMed:20220136, PubMed:24236072). Interacts with the essential precursor of cell wall synthesis lipid II to inhibit bacterial cell wall synthesis (PubMed:20214904). Inhibits adenovirus infection via inhibition of viral disassembly at the vertex region, thereby restricting the release of internal capsid protein pVI, which is required for endosomal membrane penetration during cell entry (PubMed:18191790). In addition, interaction with adenovirus capsid leads to the redirection of viral particles to TLR4 thereby promoting a NLRP3-mediated inflammasome response and interleukin 1-beta (IL-1beta) release (PubMed:35080426). Induces the production of proinflammatory cytokines including type I interferon (IFN) in plasmacytoid dendritic cells (pDCs) by triggering the degradation of NFKBIA and nuclear translocation of IRF1, both of which are required for activation of pDCs (PubMed:27031443)

The "DEFA1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFA1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets